APO Research
Talk to an analyst

APO RESEARCH · REPORT

PARP (Poly ADP-Ribose Polymerase) Inhibitor

PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).

They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment.

In our report, we only study four approved PARPi (Lynparza, Zejula, Rubraca and Talzenna). One unit is one tablet or one capsule.

Selected research

Market Outlook & Growth Opportunities

Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Outlook and Growth Opportunities 2026

21 December 2025191 pages

Choose your research edition.

Industry ResearchPARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal PARP (Poly ADP-Ribose Polymerase) Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).

They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment.

In our report, we only study four approved PARPi (Lynparza, Zejula, Rubraca and Talzenna). One unit is one tablet or one capsule.

Read the full market overview

Global PARP (Poly ADP-Ribose Polymerase) Inhibitor key players include AstraZeneca, Tesaro, Merck & Co, etc. Global top three manufacturers hold a share about 90%.

North America is the largest market, with a share about 70%, followed by Europe and Emerging Country, both have a share about 25 percent.

In terms of product, Lynparza is the largest segment, with a share over 65%. And in terms of application, the largest application is Ovarian Cancer, followed by Breast Cancer.

This report provides an overview of the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of PARP (Poly ADP-Ribose Polymerase) Inhibitor and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents PARP (Poly ADP-Ribose Polymerase) Inhibitor sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the PARP (Poly ADP-Ribose Polymerase) Inhibitor market size, projected growth trends, production technologies, key applications, and end-use industries.

PARP (Poly ADP-Ribose Polymerase) Inhibitor Segment by Company

AstraZeneca

Tesaro

Merck & Co

Clovis Oncology

Pfizer

GSK

Zai Lab

PARP (Poly ADP-Ribose Polymerase) Inhibitor Segment by Type

Lynparza

Zejula

Rubraca

Talzenna

Other

PARP (Poly ADP-Ribose Polymerase) Inhibitor Segment by Application

Ovarian Cancer

Breast Cancer

Other

PARP (Poly ADP-Ribose Polymerase) Inhibitor Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global PARP (Poly ADP-Ribose Polymerase) Inhibitor status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions PARP (Poly ADP-Ribose Polymerase) Inhibitor market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify PARP (Poly ADP-Ribose Polymerase) Inhibitor significant trends, drivers, influence factors in global and regions.

6. To analyze PARP (Poly ADP-Ribose Polymerase) Inhibitor competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PARP (Poly ADP-Ribose Polymerase) Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PARP (Poly ADP-Ribose Polymerase) Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the PARP (Poly ADP-Ribose Polymerase) Inhibitor market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global PARP (Poly ADP-Ribose Polymerase) Inhibitor industry.

Chapter 3: Detailed analysis of PARP (Poly ADP-Ribose Polymerase) Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of PARP (Poly ADP-Ribose Polymerase) Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of PARP (Poly ADP-Ribose Polymerase) Inhibitor in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Trends Table 2. PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Drivers Table 3. PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Opportunities and Challenges Table 4. PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Restraints Table 5. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Company (US$ Million) & (2021-2026) Table 6. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Company (2021-2026) Table 7. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Volume by Company (k units) & (2021-2026) Table 8. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Volume Share by Company (2021-2026) Table 9. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price (USD/unit) of Company (2021-2026) Table 10. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Company Ranking, (2024-2026) & (USD Million) Table 11. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Key Company Manufacturing Base & Headquarters Table 12. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Company, Product Type & Application Table 13. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Lynparza Table 18. Significant Companies of Zejula Table 19. Significant Companies of Rubraca Table 20. Significant Companies of Talzenna Table 21. Significant Companies of Other Table 22. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 23. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Volume by Type (2021-2026) & (k units) Table 24. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Volume by Type (2027-2032) & (k units) Table 25. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Volume Share by Type (2021-2026) Table 26. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Volume Share by Type (2027-2032) Table 27. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type (2021-2026) Table 31. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Ovarian Cancer Table 33. Significant Companies of Breast Cancer Table 34. Significant Companies of Other Table 35. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Volume by Application (2021-2026) & (k units) Table 37. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Volume by Application (2027-2032) & (k units) Table 38. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Volume Share by Application (2021-2026) Table 39. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Volume Share by Application (2027-2032) Table 40. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application (2021-2026) Table 44. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application (2027-2032) Table 45. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 46. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2021-2026) & (k units) Table 47. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Region (2021-2026) Table 48. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2027-2032) & (k units) Table 49. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Region (2027-2032) Table 50. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Region (2021-2026) Table 53. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Region (2027-2032) Table 55. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Average Price (USD/unit) by Region (2021-2026) Table 56. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Average Price (USD/unit) by Region (2027-2032) Table 57. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 58. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2021-2026) & (k units) Table 60. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country (2021-2026) Table 61. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2027-2032) & (k units) Table 62. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country (2027-2032) Table 63. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Market Share by Country (2021-2026) Table 65. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Market Share by Country (2027-2032) Table 67. AstraZeneca Company Information Table 68. AstraZeneca Business Overview Table 69. AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 70. AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio Table 71. AstraZeneca Recent Development Table 72. Tesaro Company Information Table 73. Tesaro Business Overview Table 74. Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 75. Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio Table 76. Tesaro Recent Development Table 77. Merck & Co Company Information Table 78. Merck & Co Business Overview Table 79. Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 80. Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio Table 81. Merck & Co Recent Development Table 82. Clovis Oncology Company Information Table 83. Clovis Oncology Business Overview Table 84. Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 85. Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio Table 86. Clovis Oncology Recent Development Table 87. Pfizer Company Information Table 88. Pfizer Business Overview Table 89. Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 90. Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio Table 91. Pfizer Recent Development Table 92. GSK Company Information Table 93. GSK Business Overview Table 94. GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 95. GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio Table 96. GSK Recent Development Table 97. Zai Lab Company Information Table 98. Zai Lab Business Overview Table 99. Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 100. Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio Table 101. Zai Lab Recent Development Table 102. Key Raw Materials Table 103. Raw Materials Key Suppliers Table 104. PARP (Poly ADP-Ribose Polymerase) Inhibitor Distributors List Table 105. PARP (Poly ADP-Ribose Polymerase) Inhibitor Customers List Table 106. Research Programs/Design for This Report Table 107. Authors List of This Report Table 108. Secondary Sources Table 109. Primary Sources List of Figures Figure 1. PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Image Figure 2. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 4. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (2021-2032) & (k units) Figure 5. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Average Price (USD/unit) & (2021-2032) Figure 6. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Lynparza Image Figure 10. Zejula Image Figure 11. Rubraca Image Figure 12. Talzenna Image Figure 13. Other Image Figure 14. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Volume Share by Type (2021-2032) Figure 17. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type (2021-2032) Figure 20. Ovarian Cancer Image Figure 21. Breast Cancer Image Figure 22. Other Image Figure 23. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Volume Share by Application (2021-2032) Figure 26. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application (2021-2032) Figure 29. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 30. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 34. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 36. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 40. South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. PARP (Poly ADP-Ribose Polymerase) Inhibitor Value Chain Figure 128. Manufacturing Cost Structure Figure 129. PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Lynparza
  • Zejula
  • Rubraca
  • Talzenna
  • Other
Applications
  • Ovarian Cancer
  • Breast Cancer
  • Other
Companies covered
  • AstraZeneca
  • Tesaro
  • Merck & Co
  • Clovis Oncology
  • Pfizer
  • GSK
  • Zai Lab

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value (2021-2032)
  4. 1.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Volume (2021-2032)
  5. 1.2.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Dynamics
  1. 2.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Trends
  2. 2.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Drivers
  3. 2.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Opportunities and Challenges
  4. 2.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Restraints
3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market by Company
  1. 3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Company Revenue Ranking in 2025
  2. 3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Company (2021-2026)
  3. 3.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Volume by Company (2021-2026)
  4. 3.4 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price by Company (2021-2026)
  5. 3.5 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Company Ranking (2024-2026)
  6. 3.6 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Company Manufacturing Base and Headquarters
  7. 3.7 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Company Product Type and Application
  8. 3.8 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 PARP (Poly ADP-Ribose Polymerase) Inhibitor Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market by Type
  1. 4.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Type Introduction
  2. 4.1.1 Lynparza
  3. 4.1.2 Zejula
  4. 4.1.3 Rubraca
  5. 4.1.4 Talzenna
  6. 4.1.5 Other
  7. 4.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Volume by Type
  8. 4.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Volume by Type (2021-2032)
  10. 4.2.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Volume Share by Type (2021-2032)
  11. 4.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value by Type
  12. 4.3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value by Type (2021-2032)
  14. 4.3.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type (2021-2032)
5 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market by Application
  1. 5.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Application Introduction
  2. 5.1.1 Ovarian Cancer
  3. 5.1.2 Breast Cancer
  4. 5.1.3 Other
  5. 5.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Volume by Application
  6. 5.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Volume by Application (2021-2032)
  8. 5.2.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Volume Share by Application (2021-2032)
  9. 5.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value by Application
  10. 5.3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value by Application (2021-2032)
  12. 5.3.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application (2021-2032)
6 PARP (Poly ADP-Ribose Polymerase) Inhibitor Regional Sales and Value Analysis
  1. 6.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2021-2032)
  3. 6.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region: 2021-2026
  4. 6.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2027-2032)
  5. 6.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value by Region (2021-2032)
  7. 6.4.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value by Region: 2021-2026
  8. 6.4.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value by Region (2027-2032)
  9. 6.5 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value (2021-2032)
  12. 6.6.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value (2021-2032)
  15. 6.7.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value (2021-2032)
  21. 6.9.2 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Country, 2025 VS 2032
7 PARP (Poly ADP-Ribose Polymerase) Inhibitor Country-level Sales and Value Analysis
  1. 7.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2021-2032)
  4. 7.3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2021-2026)
  5. 7.3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2027-2032)
  6. 7.4 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value by Country (2021-2032)
  7. 7.4.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value by Country (2021-2026)
  8. 7.4.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AstraZeneca
  2. 8.1.1 AstraZeneca Company Information
  3. 8.1.2 AstraZeneca Business Overview
  4. 8.1.3 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
  6. 8.1.5 AstraZeneca Recent Developments
  7. 8.2 Tesaro
  8. 8.2.1 Tesaro Company Information
  9. 8.2.2 Tesaro Business Overview
  10. 8.2.3 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
  12. 8.2.5 Tesaro Recent Developments
  13. 8.3 Merck & Co
  14. 8.3.1 Merck & Co Company Information
  15. 8.3.2 Merck & Co Business Overview
  16. 8.3.3 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
  18. 8.3.5 Merck & Co Recent Developments
  19. 8.4 Clovis Oncology
  20. 8.4.1 Clovis Oncology Company Information
  21. 8.4.2 Clovis Oncology Business Overview
  22. 8.4.3 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
  24. 8.4.5 Clovis Oncology Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 GSK
  32. 8.6.1 GSK Company Information
  33. 8.6.2 GSK Business Overview
  34. 8.6.3 GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
  36. 8.6.5 GSK Recent Developments
  37. 8.7 Zai Lab
  38. 8.7.1 Zai Lab Company Information
  39. 8.7.2 Zai Lab Business Overview
  40. 8.7.3 Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
  42. 8.7.5 Zai Lab Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Value Chain Analysis
  2. 9.1.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Mode & Process
  6. 9.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Distributors
  9. 9.2.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst